Download BUT WE CAN DO MORE AT LEAST ONE NEW CANCER PATIENT

THE GARRON FAMILY
CANCER CENTRE
By providing world-class care and developing
tomorrow’s revolutionary therapies, the Garron Family
Cancer Centre is changing the future for patients and
families affected by childhood cancer.
ABOUT CHILDHOOD CANCER
CANCER IS THE SECOND LEADING CAUSE
OF DEATH IN CHILDHOOD AFTER ACCIDENTS.
With a mortality rate of close to 25%, Canada loses tens of thousands of
years of potential life each year to childhood cancer.
6
5
4
4
3
3
2
2
of these children will experience lifelong
chronic conditions resulting from their
treatment that impact the quality and
length of their lives.
1
2/3
5
6
BUT DESPITE THE CURE RATE,
1
SURVIVAL RATE
GROWTH &
DEVELOPMENT
0
PER CENT
0
83
HOWEVER, THANKS TO ADVANCES IN RESEARCH, EDUCATION AND CARE, MORE
THAN 83 PER CENT OF CHILDREN DIAGNOSED WITH CANCER WILL SURVIVE!
ORGAN
FUNCTION
CONDITIONS AFFECTING AREAS OF LIFE SUCH AS
REPRODUCTIVE
CAPACITY
SICKKIDS SEES
HOW SICKKIDS HELPS
AT LEAST ONE NEW
CANCER PATIENT
EVERY DAY
IN 2015, 350 CHILDREN WERE DIAGNOSED
WITH CANCER AT SICKKIDS
(An average of 4 per day)
Last year at SickKids
there were:
851
Chemotherapy
treatments
114
Radiation
treatments
82
BUT WE CAN DO MORE
Brain tumour
patients treated
1ST
2ND
THE MIBG SUITE OFFERS A NEW TREATMENT
OPTION FOR CHILDREN FROM ACROSS
CANADA WITH RELAPSED NEUROBLASTOMA.
Neuroblastoma is the most common solid cancer in childhood
and the most common cancer in infancy.
GARRON FAMILY MIBG SUITE
SickKids is home to the largest
oncology training program in the
country and has trained nearly 80
per cent of all practicing paediatric
oncology specialists in Canada.
In 2013, SickKids opened the Garron
Family MIBG Suite. It is the first
paediatric MIBG centre in Ontario,
second in Canada, and only one of
13 in North America.
In 2015, the Garron Family Cancer
Centre had more than 150 children
from across Canada enrolled in 54
clinical trials.
1976
2003
2010
Canada’s first bone marrow transplant
program began at SickKids. Today, SickKids
has one of the two largest bone marrow
transplant programs in North America.
SickKids researchers identified a cancer stem cell in
both malignant and benign brain tumours. This
discovery is changing how brain tumours are studied
and how this life-threatening condition is treated.
In 2010, SickKids scientists learned
the most common childhood brain
tumour, medulloblastoma, is actually
four distinct forms of cancer.
2011
2012
2014
SickKids scientists developed a new
approach for the early detection of cancer
in children genetically predisposed by
Li-Fraumeni Syndrome.
A study led by SickKids revealed
a possible method of removing leukemia
stem cells, preventing relapse of acute
myeloid leukemia.
SickKids researchers discovered why
ependymoma, a brain tumour affecting
babies and toddlers, is resistant to
chemotherapy.
THE FUTURE
SickKids is changing the
future of childhood cancer.
BE A PART OF IT.
SickKids researchers
are deepening our
understanding of how
cancers differ from
patient to patient – and
from tumour to tumour.
As the leading Canadian site
for international paediatric
oncology clinical trials, SickKids
is making childhood cancer
clinical trials more accessible
to Canadian patients.
Clinical trials bridge advances
made in the laboratory with
improved patient care and
offer treatment options for
children who have exhausted
all conventional therapies.
ADVANCES IN GENETICS AND MOLECULAR BIOLOGY HAVE
TRANSFORMED THE WAY WE UNDERSTAND CANCER.
Using precision medicine, SickKids is identifying effective new ways to treat
childhood cancer based on the patient’s individual tumour profile. This will also
result in treatments that are less toxic and reduce the risk of future health issues.
If you have any questions regarding
the information included in this fact
sheet, please contact:
PHONE
416-813-6166
1-800-661-1083
EMAIL
[email protected]